New research from Lund University in Sweden has shown that intestinal bacteria can accelerate the development of Alzheimer’s disease. According to the researchers behind the study, the results open up the door to new opportunities for preventing and treating the disease.
Because our gut bacteria have a major impact on how we feel through the interaction between the immune system, the intestinal mucosa and our diet, the composition of the gut microbiota is of great interest to research on diseases such as Alzheimer’s. Exactly how our gut microbiota composition is composed depends on which bacteria we receive at birth, our genes and our diet.
By studying both healthy and diseased mice, the researchers found that mice suffering from Alzheimer’s have a different composition of gut bacteria compared to mice that are healthy. The researchers also studied Alzheimer’s disease in mice that completely lacked bacteria to further test the relationship between intestinal bacteria and the disease. Mice without bacteria had a significantly smaller amount of beta-amyloid plaque in the brain. Beta-amyloid plaques are the lumps that form at the nerve fibres in cases of Alzheimer’s disease.
To clarify the link between intestinal flora and the occurrence of the disease, the researchers transferred intestinal bacteria from diseased mice to germ-free mice, and discovered that the mice developed more beta-amyloid plaques in the brain compared to if they had received bacteria from healthy mice.
“Our study is unique as it shows a direct causal link between gut bacteria and Alzheimer’s disease. It was striking that the mice which completely lacked bacteria developed much less plaque in the brain,” says researcher Frida Fåk Hållenius, at the Food for Health Science Centre.
“The results mean that we can now begin researching ways to prevent the disease and delay the onset. We consider this to be a major breakthrough as we used to only be able to give symptom-relieving antiretroviral drugs.”
The research is a result of an international collaboration between Associate Professor Frida Fåk Hållenius and doctoral student Nittaya Marungruang, both at the Food for Health Science Centre in Lund, and a research group at the Ecole Polytechnique Federale de Lausanne in Switzerland. The collaboration has now expanded to include researchers from Germany and Belgium in connection with receiving a SEK 50 million EU grant.
The researchers will continue to study the role of bacteria in the development of Alzheimer’s disease, and test entirely new types of preventive and therapeutic strategies based on the modulation of the gut microbiota through diet and new types of probiotics.
Source: T. Harach, N. Marungruang, N. Duthilleul, V. Cheatham, K. D. Mc Coy, G. Frisoni, J. J. Neher, F. Fåk, M. Jucker, T. Lasser, T. Bolmont. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Scientific Reports, 2017; 7: 41802 DOI: 10.1038/srep41802
